Pay in 4 interest-free payments of $7.24 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
PMID: 32745763
Pregnant and nursing women should not take this treatment
Use within 24 months from the manufacturing date
Semaglutide incorporates structural modifications that enhance molecular stability compared with native GLP-1 peptides
For a broader primer on how research peptides are sourced, tested, and classified, see our complete peptide sciences research guide
Victoza is a once-daily GLP-1 RA therapy for patients with type 2 diabetes Indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes and to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes and established cardiovascular disease
